.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Covington
Accenture
Merck
Julphar
UBS
McKinsey
Fuji
Mallinckrodt

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,294,540

« Back to Dashboard

Which drugs does patent 6,294,540 protect, and when does it expire?


Patent 6,294,540 protects ZIAGEN, EPZICOM, TRIUMEQ, and TRIZIVIR, and is included in five NDAs. There have been zero Paragraph IV challenges on Triumeq, Ziagen, Trizivir, and .

Protection for ZIAGEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-nine patent family members in forty-eight countries.

Summary for Patent: 6,294,540

Title: Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Abstract:The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Inventor(s): Brodie; Alastair Couper (London, GB), Jones; Martin Francis (Kneloworth, GB), Seager; John Frederick (Ware, GB), Wallis; Christopher John (Rayston, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/423,982
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Viiv HlthcareZIAGENabacavir sulfateSOLUTION;ORAL020978-001Dec 17, 1998AARXYesYes► Subscribe► Subscribe► SubscribeY
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeY
Viiv HlthcareTRIUMEQabacavir sulfate; dolutegravir sodium; lamivudineTABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY
Viiv HlthcareZIAGENabacavir sulfateTABLET;ORAL020977-001Dec 17, 1998ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,294,540

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9709945May 17, 1997
PCT Information
PCT FiledMay 14, 1998PCT Application Number:PCT/EP98/02835
PCT Publication Date:November 26, 1998PCT Publication Number: WO98/52949

International Patent Family for Patent: 6,294,540

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)2009► Subscribe
Argentina012702► Subscribe
Argentina015668► Subscribe
Argentina059120► Subscribe
Austria259811► Subscribe
Australia739953► Subscribe
Australia7765598► Subscribe
Australia7912398► Subscribe
Australia8017298► Subscribe
Bulgaria103959► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Baxter
US Army
Healthtrust
US Department of Justice
McKinsey
McKesson
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot